Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental spinal cord injury.
about
Drug delivery, cell-based therapies, and tissue engineering approaches for spinal cord injuryA grading system to evaluate objectively the strength of pre-clinical data of acute neuroprotective therapies for clinical translation in spinal cord injury.Erythropoietin protects from post-traumatic edema in the rat brain.Dantrolene can reduce secondary damage after spinal cord injuryBiochanin A reduces drug-induced p75NTR expression and enhances cell survival: a new in vitro assay for screening inhibitors of p75NTR expressionPromises and pitfalls in erythopoietin-mediated tissue protection: are nonerythropoietic derivatives a way forward?Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities.A systematic review of non-invasive pharmacologic neuroprotective treatments for acute spinal cord injury.Delayed administration of pyroglutamate helix B surface peptide (pHBSP), a novel nonerythropoietic analog of erythropoietin, attenuates acute kidney injury.Transplantation of erythropoietin gene-modified neural stem cells improves the repair of injured spinal cordMaladaptive spinal plasticity opposes spinal learning and recovery in spinal cord injury.MP Resulting in Autophagic Cell Death of Microglia through Zinc Changes against Spinal Cord InjuryPharmacological preconditioning with erythropoietin attenuates the organ injury and dysfunction induced in a rat model of hemorrhagic shock.Erythropoietin in spinal cord injury.Inflammatory and structural biomarkers in acute traumatic spinal cord injury.Viability-dependent promoting action of adult neural precursors in spinal cord injury.Combination therapies for traumatic brain injury: prospective considerations.Erythropoietin: recent developments in the treatment of spinal cord injuryCorticosteroids and erythropoeitin-receptor agonists.Acute spinal cord injury persistently reduces R/G RNA editing of AMPA receptors.Efficacy of combination therapy with erythropoietin and methylprednisolone in clinical recovery of severe relapse in multiple sclerosis.Multifunctional nanoparticles for gene delivery and spinal cord injury.EPO-releasing neural precursor cells promote axonal regeneration and recovery of function in spinal cord traumatic injury.Kainate receptor RNA editing is markedly altered by acute spinal cord injury.Effects of erythropoietin and methylprednisolone on AQP4 expression in astrocytes.Decreased GFAP expression and improved functional recovery in contused spinal cord of rats following valproic acid therapy.Tolerability and efficacy of erythropoietin (EPO) treatment in traumatic spinal cord injury: a preliminary randomized comparative trial vs. methylprednisolone (MP).Enhanced brain release of erythropoietin, cytokines and NO during carotid clamping.Delayed administration of recombinant human erythropoietin reduces apoptosis and inflammation and promotes myelin repair and functional recovery following spinal cord compressive injury in rats.Abstracts of the XXVII Italian Society for the Study of Connective Tissues (SISC) Meeting, Bologna, Italy, 8-10 November 2007Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis
P2860
Q28085174-FEAF391B-F7F4-42BA-BCD0-3B033B6A9715Q30502819-CF4DC58E-3205-4C8F-8F0C-DF2218DCE423Q31096583-BC2FE807-FBB4-4EB0-9314-6FD7D62E5A7DQ33971965-A27743E2-7BD1-4DBD-9C84-F384D27BEE8FQ34421141-1FB546BE-28F9-4430-993D-FD846586A568Q34504572-A400AA20-6781-4E20-96B7-D7DF792E3A47Q34596211-C2939056-E4C1-49F7-8693-8F1230A0A2B6Q35127468-80933DFE-BC9A-403C-8F62-1345BBB3E730Q36071692-C047E2EB-3A84-447F-AB6D-227351D21D24Q36222826-EBB627EB-256D-4023-8D20-62E7C9B8FE9BQ36308081-3A369D54-E754-42F9-9985-A1841EDAD47AQ36530866-F6DE18D3-0BBB-435D-97C1-A79F5DEED8A4Q36790949-E99ED076-5B7E-4492-AA55-DB8CE97F9815Q37334021-7B969E9B-9E63-440B-8721-48ED141CD442Q37822789-4B8C3AD8-98DF-44EA-B9E5-9B5505C21120Q40797863-D9708608-06D4-4FC5-A3E6-E801988D67A9Q42616360-F7784403-9460-46FE-B2DD-BEE67039392FQ42797884-192182EC-A33C-411D-B062-F68D3ED37C2FQ42860555-AB8FA8B7-7BA0-4430-BAD0-AD8A00CB456FQ43067888-2C4B0457-1B0A-4E7A-90E4-198B2BB7006FQ45076147-84B8FC76-D3FA-41C9-9835-EC05F2198B5BQ45875230-99EF542B-0D9A-432B-B5B0-20ACF1FF86EAQ47163853-2D879685-E3AC-4186-9A1A-19EBB32CBBBDQ47693496-34AEB7FF-4D62-4DDA-8EB8-BF952C0C1D55Q47891143-6AD86B5A-9352-4B6C-86CA-C3DFB1BCC06BQ48554189-5A0BF6E8-FF84-475E-B03E-00FE4504C2F1Q50940964-219446DC-8701-43BF-9A4D-DB0317162E30Q52147638-F4FEF08D-995B-460C-9763-E82333068300Q52911693-F4C84614-D7D9-4368-ADE9-F7CF0962A6FFQ56996309-1C34D121-A52D-4383-A4B7-D1648D81D265Q59264385-AD222B8C-D4DD-47C5-BF45-4AFCE62BE8F4
P2860
Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental spinal cord injury.
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Methylprednisolone neutralizes ...... perimental spinal cord injury.
@ast
Methylprednisolone neutralizes ...... perimental spinal cord injury.
@en
Methylprednisolone neutralizes ...... perimental spinal cord injury.
@nl
type
label
Methylprednisolone neutralizes ...... perimental spinal cord injury.
@ast
Methylprednisolone neutralizes ...... perimental spinal cord injury.
@en
Methylprednisolone neutralizes ...... perimental spinal cord injury.
@nl
prefLabel
Methylprednisolone neutralizes ...... perimental spinal cord injury.
@ast
Methylprednisolone neutralizes ...... perimental spinal cord injury.
@en
Methylprednisolone neutralizes ...... perimental spinal cord injury.
@nl
P2093
P2860
P50
P356
P1476
Methylprednisolone neutralizes ...... xperimental spinal cord injury
@en
P2093
Alfredo Gorio
Anthony Cerami
Laura Madaschi
Silvia De Biasi
Stephana Carelli
Thomas Coleman
P2860
P304
16379-16384
P356
10.1073/PNAS.0508479102
P407
P577
2005-10-31T00:00:00Z